Your browser doesn't support this page

This website uses the latest technology, and it looks like your browser doesn't support some of the latest features.

You'll probably be able to see the content with the browser you have, but we encourage you to choose a browser with better support for the future of the web. These support all the features used (and they're free too):

Google Chrome Mozilla Firefox Safari Dismiss
Andreas Kleppe

Contact information

Please contact Andreas Kleppe for more information

Prostate Nucleotyping

The Gray Level Entropy Matrix (GLEM), the backbone of Nucleotyping, was developed using a collection of tumor tissues from patients with advanced prostate cancer (SPCG-2), and increased entropy was shown to significantly correlate with poor survival.

Recently, a more advanced version of Nucleotyping was used to analyze a minimum of three blocks of prostate tumor from 314 patients, in the search for prognostic markers for relapse after surgery. We found distinct chromatin changes in the periphery of small nuclei, characteristic of patients with increased risk of relapse or cancer death. We have demonstrated that Nucleotyping is an independent prognostic marker with particular value for patients with a Gleason score of 7.

Related articles

Chief Editor: Prof. HÃ¥vard E. Danielsen
Copyright Oslo University Hospital. Visiting address: The Norwegian Radium Hospital, Ullernchausséen 64, Oslo. Tel: 22 78 23 20